Liminatus Pharma Engages Synex as CRO to Advance IBC101 CD19xCD22 Bivalent CAR-T Therapy in South Korea
核心洞察
Liminatus Pharma (搜索) has engaged Korea-based CRO Synex Consulting Ltd. (搜索) to support clinical development of IBC101 (搜索), its CD19xCD22 bivalent CAR-T cell therapy candidate.
IBC101 (搜索) has received MFDS authorization for a Phase 1/2a study in relapsed or refractory diffuse large B-cell lymphoma (搜索), with Seoul St. Mary's Hospital as the lead site.
The dual-targeting OR-gate CAR-T design aims to broaden antigen coverage and address antigen escape and tumor heterogeneity associated with single-antigen CAR-T relapse.
Liminatus Pharma (搜索), Inc. (Nasdaq: LIMN), a biotechnology company developing innovative cancer therapies, announced on Aug. 24, 2026 that it has engaged Synex Consulting Ltd. (搜索), a Korea-based full-service contract research organization (CRO), to support the clinical development of IBC101 (搜索), the Company's CD19xCD22 bivalent CAR-T cell therapy candidate.
The engagement represents an important step in advancing IBC101 (搜索) toward clinical execution in South Korea. IBC101 has received authorization from the Ministry of Food and Drug Safety of the Republic of Korea (MFDS) for a Phase 1/2a clinical study in patients with relapsed or refractory diffuse large B-cell lymphoma (搜索) (DLBCL), with Seoul St. Mary's Hospital identified as the lead clinical site.
Under the engagement, Synex will provide clinical research services pursuant to a milestone-based program, with payments linked to key clinical development milestones, including patient enrollment, database lock and completion of the clinical study report.
"Engaging Synex is another important step in moving IBC101 (搜索) from regulatory authorization toward clinical execution," said Chris Kim, Chief Executive Officer of Liminatus. "Synex brings extensive experience supporting pharmaceutical clinical development in Korea, and we believe its local regulatory and clinical capabilities will be valuable as we advance the IBC101 Phase 1/2a program."
Dual-Antigen Targeting to Counter Relapse
IBC101 (搜索) is an autologous CD19xCD22 bivalent CAR-T cell therapy designed for relapsed or refractory B-cell malignancies. The candidate utilizes an OR-gate approach intended to recognize malignant B cells expressing either CD19 (搜索) or CD22 (搜索). By targeting two established B-cell antigens, IBC101 is designed to broaden antigen coverage and potentially address antigen escape and tumor heterogeneity, two mechanisms associated with relapse following single-antigen CAR-T therapy.
The therapy is designed as an OR-gate CAR-T system capable of recognizing tumor cells expressing either CD19 (搜索) or CD22 (搜索), with the goal of expanding antigen coverage and reducing the potential for antigen escape associated with single-target CAR-T therapies.
Expanding the Oncology Portfolio
The IBC101 (搜索) program further expands Liminatus' oncology development portfolio beyond its IBA101 (搜索) CD47 (搜索) checkpoint inhibitor program and establishes an additional clinical-stage development pathway focused on hematologic malignancies.
"Following the expansion of our oncology portfolio, our focus is increasingly shifting toward execution across our development programs," added Mr. Kim. "The Synex engagement provides clinical infrastructure in Korea to support the next stage of IBC101 (搜索)'s development, and we look forward to progressing the program toward patient enrollment."
Liminatus Pharma (搜索), Inc. is a biotechnology company developing innovative immuno-oncology and cell therapy candidates. The Company's portfolio includes IBA101 (搜索), a next-generation anti-CD47 (搜索) monoclonal antibody, as well as oncology-focused cellular therapy programs including IBC101 (搜索), a CD19xCD22 bivalent CAR-T candidate for B-cell malignancies. Liminatus is focused on advancing differentiated therapeutic approaches designed to address significant unmet needs in cancer treatment.